MORGAN STANLEY PLC/CALL/INCYTE CO./60/0.5/20.12.24 | Market Closed - Börse Stuttgart 09:49:49 28/06/2024 pm IST | ||
| 2.75 EUR | -9.54% |
|
| Current month | +23.32% | ||
| 1 month | +38.19% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
INCYTE CORPORATION
Latest news about INCYTE CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 28/24/28 | 2.75 | -9.54% |
| 27/24/27 | 3.04 | -5.59% |
| 26/24/26 | 3.22 | -15.49% |
| 25/24/25 | 3.81 | -4.27% |
| 24/24/24 | 3.98 | +7.86% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 09:49 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | INCYTE CORPORATION |
| Issuer | Morgan Stanley |
| WKN | ME9H2Y |
| ISIN | DE000ME9H2Y1 |
| Date issued | 01/03/2024 |
| Strike | 60 $ |
| Maturity | 20/12/2024 (173 Days) |
| Parity | 2 : 1 |
| Emission price | 4.1 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.55 € |
|---|---|
| Lowest since issue | 1.14 € |
| Spread | 0.05 € |
| Spread % | 1.75% |
Company Profile
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows:
- product sales (85.6%);
- royalties (14.2%);
- income from research and cooperation agreements (0.2%).
Sector
-
Consensus: Incyte Corporation
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
60.62
USD
Average target price
72.8
USD
Spread / Average Target
+20.09%
- Stock Market
- Warrants
- Warrant
